Following successful anti-leishmanial treatment, neutrophil counts, CD10 expression and phagocytic capacity remain reduced in visceral leishmaniasis patients co-infected with HIV

PLoS Negl Trop Dis. 2022 Aug 15;16(8):e0010681. doi: 10.1371/journal.pntd.0010681. eCollection 2022 Aug.

Abstract

Visceral leishmaniasis (VL) patients co-infected with HIV (VL/HIV patients) experience frequent treatment failures, VL relapses, opportunistic infections, and higher mortality. Their immune system remains profoundly suppressed after clinical cure and they maintain higher parasite load. This is in contrast with patients with VL alone (VL patients). Since neutrophils play a critical role in the control of Leishmania replication and the regulation of immune responses, we tested the hypothesis that neutrophil activation status and effector functions are fully restored in VL, but not in VL/HIV patients. Our results show the neutrophil counts and all activation markers and effector functions tested in our study were reduced at the time of diagnosis in VL and VL/HIV patients as compared to controls. CD62L, CD63, arginase 1 expression levels and reactive oxygen species production were restored at the end of treatment in both groups. However, neutrophil counts, CD10 expression and phagocytosis remained significantly lower throughout follow-up in VL/HIV patients; suggesting that dysregulated neutrophils contribute to the impaired host defence against pathogens in VL/HIV patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Coinfection* / drug therapy
  • HIV Infections* / complications
  • HIV Infections* / drug therapy
  • Humans
  • Leishmania*
  • Leishmaniasis, Visceral* / complications
  • Leishmaniasis, Visceral* / drug therapy
  • Neutrophils